| Literature DB >> 33020649 |
Yoshiaki Nakamura1,2, Hiroya Taniguchi1,2, Masafumi Ikeda3, Hideaki Bando4, Ken Kato5,6, Chigusa Morizane7, Taito Esaki8, Yoshito Komatsu9, Yasuyuki Kawamoto9, Naoki Takahashi10, Makoto Ueno11, Yoshinori Kagawa12, Tomohiro Nishina13, Takeshi Kato14, Yoshiyuki Yamamoto15, Junji Furuse16, Tadamichi Denda17, Hisato Kawakami18, Eiji Oki19, Takako Nakajima20, Naohiro Nishida21, Kensei Yamaguchi22, Hisateru Yasui23, Masahiro Goto24, Nobuhisa Matsuhashi25, Koushiro Ohtsubo26, Kentaro Yamazaki27, Akihito Tsuji28, Wataru Okamoto2,29, Katsuya Tsuchihara2,30, Takeharu Yamanaka31, Izumi Miki2, Yasutoshi Sakamoto2, Hiroko Ichiki2, Masayuki Hata2, Riu Yamashita30, Atsushi Ohtsu1, Justin I Odegaard32, Takayuki Yoshino33.
Abstract
Comprehensive genomic profiling enables genomic biomarker detection in advanced solid tumors. Here, to evaluate the utility of circulating tumor DNA (ctDNA) genotyping, we compare trial enrollment using ctDNA sequencing in 1,687 patients with advanced gastrointestinal (GI) cancer in SCRUM-Japan GOZILA (no. UMIN000016343), an observational ctDNA-based screening study, to enrollment using tumor tissue sequencing in the same centers and network (GI-SCREEN, 5,621 patients). ctDNA genotyping significantly shortened the screening duration (11 versus 33 days, P < 0.0001) and improved the trial enrollment rate (9.5 versus 4.1%, P < 0.0001) without compromising treatment efficacy compared to tissue genotyping. We also describe the clonal architecture of ctDNA profiles in ~2,000 patients with advanced GI cancer, which reinforces the relevance of many targetable oncogenic drivers and highlights multiple new drivers as candidates for clinical development. ctDNA genotyping has the potential to accelerate innovation in precision medicine and its delivery to individual patients.Entities:
Mesh：
Substances：
Year: 2020 PMID： 33020649 DOI： 10.1038/s41591-020-1063-5
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440